Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions
Brain Tumor, Recurrent
Interventions
DRUG

Photofrin (porfimer sodium) & photodynamic therapy.

"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."

Trial Locations (1)

53226

Children's Hospital of Wisconsin, Wauwatosa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pinnacle Biologics Inc.

INDUSTRY

lead

Harry T Whelan, MD

OTHER

NCT01682746 - Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | Biotech Hunter | Biotech Hunter